import { BlogLiraglutideVsSemaglutide } from "../../../components/blog-liraglutide-vs-semaglutide-daily-injections-obsolete.jsx";

export const metadata = {
  robots: { index: true, follow: true },
  alternates: {
    canonical: 'https://telehealthfx.com/blog/liraglutide-vs-semaglutide-daily-injections-obsolete/',
  },
  title: "Liraglutide (Saxenda/Victoza) vs. Semaglutide: Why Daily Injections Are Obsolete in 2026",
  description: "Head-to-head comparison of liraglutide vs semaglutide. STEP 8 trial data, half-life differences, weight loss results, and why daily GLP-1 injections are no longer the clinical standard in 2026.",
  openGraph: {
    title: "Liraglutide vs. Semaglutide: Why Daily Injections Are Obsolete in 2026",
    description: "Head-to-head comparison of liraglutide vs semaglutide. STEP 8 trial data, half-life differences, and why daily GLP-1 injections are no longer the clinical standard.",
    images: [{ url: "https://telehealthfx.com/assets/liraglutide-vs-semaglutide-featured.png", width: 1200, height: 630, alt: "Liraglutide vs Semaglutide Comparison" }],
  },
};

export default function Page() {
  const jsonLd = {
    "@context": "https://schema.org",
    "@graph": [
      {
        "@type": "MedicalWebPage",
        "@id": "https://telehealthfx.com/blog/liraglutide-vs-semaglutide-daily-injections-obsolete/#article",
        "headline": "Liraglutide (Saxenda/Victoza) vs. Semaglutide: Why Daily Injections Are Obsolete in 2026",
        "description": "Head-to-head comparison of liraglutide vs semaglutide using STEP 8 clinical trial data.",
        "image": "https://telehealthfx.com/assets/liraglutide-vs-semaglutide-featured.png",
        "author": { "@type": "Person", "name": "Julian Mercer, M.S.", "url": "https://telehealthfx.com/about", "jobTitle": "Lead Bio-Systems Analyst" },
        "publisher": { "@type": "Organization", "name": "Telehealth FX", "logo": { "@type": "ImageObject", "url": "https://telehealthfx.com/assets/logo.png" } },
        "mainEntityOfPage": { "@type": "WebPage", "@id": "https://telehealthfx.com/blog/liraglutide-vs-semaglutide-daily-injections-obsolete/" }
      },
      {
        "@type": "FAQPage",
        "@id": "https://telehealthfx.com/blog/liraglutide-vs-semaglutide-daily-injections-obsolete/#faq",
        "mainEntity": [
          { "@type": "Question", "name": "Can I switch from Saxenda to Ozempic or Wegovy?", "acceptedAnswer": { "@type": "Answer", "text": "Yes. Your clinician can transition you from daily liraglutide to weekly semaglutide by discontinuing liraglutide and starting semaglutide at the lowest dose (0.25 mg/week), then titrating upward over 16–20 weeks." } },
          { "@type": "Question", "name": "Is semaglutide safer than liraglutide?", "acceptedAnswer": { "@type": "Answer", "text": "Both drugs share an identical safety profile regarding GLP-1 class-wide warnings. The side effect experience is similar, though semaglutide's longer half-life means nausea can persist longer when it occurs." } },
          { "@type": "Question", "name": "What about the Saxenda weight loss plateau?", "acceptedAnswer": { "@type": "Answer", "text": "Weight loss plateaus on Saxenda are common at 4–6 months when maximum 3.0 mg daily dose is reached. Unlike semaglutide and tirzepatide, there is no dose escalation pathway beyond this point." } }
        ]
      }
    ]
  };

  return (
    <>
      <script type="application/ld+json" dangerouslySetInnerHTML={{ __html: JSON.stringify(jsonLd) }} />
      <BlogLiraglutideVsSemaglutide />
    </>
  );
}
